Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 5/20 | 0.44 |
| ▸ | STS | P08842 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9336832 | 0.93 | NR1I2 (0.50) | NR1I2HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL8862087 | 0.84 | ALDH1A1 (0.45) | NR1I2HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL20382586 | 0.83 | CA1 (0.53) | HDAC1HDAC8HDAC3HDAC2ALDH1A1 | |
| SCHEMBL12981549 | 0.83 | HTT (0.44) | NR1I2HDAC1HDAC3HDAC2ALDH1A1 | |
| SCHEMBL31618944 | 0.82 | MAPT (0.46) | NR1I2HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL810463 | 0.81 | MAPT (0.45) | NR1I2HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL809790 | 0.81 | MAPT (0.44) | NR1I2HDAC1HDAC8HDAC3HDAC2 | |
| SCHEMBL27944125 | 0.80 | HSD17B3 (0.62) | ALDH1A1LMNA | |
| SCHEMBL2010661 | 0.80 | L3MBTL1 (0.49) | ALDH1A1LMNA | |
| SCHEMBL28209780 | 0.80 | HSD17B3 (0.62) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240499-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | DOW GLOBAL TECHNOLOGIES LLC | 2017-08-24 | — | — | US | disclosed |
| WO-2016057771-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | DOW GLOBAL TECHNOLOGIES LLC (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240499-A1 | METHOD FOR COUPLING A FIRST COMPOUND TO A SECOND COMPOUND | SQLE, FDPS, PAICS | NR1I2 3882/4885CNR1 1305/4885HDAC1 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.